

Special Issue

Development of Vaccines Against Bacterial Infections

Message from the Guest Editors

The Special Issue aims at providing a comprehensive overview of the current state of research in the field of vaccine development against bacterial infections. Bacterial infections continue to pose significant challenges to public health worldwide. This Special Issue will cover a wide range of topics related to bacterial vaccine development, including advances in vaccine design, mechanisms of bacterial pathogenesis, the preclinical and clinical evaluation of vaccine candidates, the use of bacteria in vaccine development, and strategies for vaccine delivery and formulation. Contributions from leading researchers and experts in the field will provide insights into the latest scientific advancements, challenges, and opportunities in the development of vaccines against bacterial infections. The goal of this Special Issue is to foster collaboration and knowledge exchange among scientists, clinicians, policymakers, and industry stakeholders to accelerate the development of effective vaccines that can mitigate the burden of bacterial diseases and improve global health outcomes.

Guest Editors

Prof. Dr. John Hwa Lee

Department of Veterinary Medicine, Jeonbuk National University,
Jeonju, Republic of Korea

Prof. Dr. Amal Senevirathne

College of Veterinary Medicine, Jeonbuk National University, Iksan
54596, Republic of Korea

Deadline for manuscript submissions

closed (30 September 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/201202

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).